The antidepressant activity of inositol in the forced swim test involves 5-HT2 receptors

Behavioural Brain Research

Volumn 118, Issue 1, 2001, Pages 77-83

  Einat, H ^a   Clenet, F ^b   Shaldubina, A ^a   Belmaker, R H ^a   Bourin, M ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT2; Depression; Forced swim test; Inositol; Serotonin receptors

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FENCLONINE; INOSITOL; NEUROTOXIN; PINDOLOL; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG MECHANISM; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZYLAMINES; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FENCLONINE; INOSITOL; MALE; MICE; NEUROTRANSMITTER UPTAKE INHIBITORS; PINDOLOL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RITANSERIN; SWIMMING; TETRAHYDRONAPHTHALENES;

EID: 0035825281     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00314-4     Document Type: Article

References (38)

1. Catecholamines in depression
2. Inositol treatment of Alzheimer's disease
3. Double blind controlled trial of inositol treatment of panic disorder
4. 1A receptors in augmenting antidepressant activity in the mouse forced swim test
5. Physiopharmacological interactions between stress hormones and central serotonergic systems
6. Lithium and inositol lipid-linked signaling mechanisms
7. Rat brain monoamines after acute and chronic myo-inositol treatment
8. Inositol reduces depressive-like behaviors in two animal models of depression
9. Inositol treatment of obsessive-compulsive disorder
10. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: A double blind crossover study
11. Hippocampal mediation of raphe lesion- and PCPA-induced hyperactivity in rats
12. The effects of alaproclate and p-chlorophenylalanin on cued navigation performance in rats
13. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorder: A double-blind randomised trial
14. Chronic dietary inositol enhances locomotor activity and brain inositol levels in rats
15. The anxiolytic effect of chronic inositol depends on the baseline level of anxiety
16. Action mechanisms of depression
17. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients
18. Controlled trials of inositol in psychiatry
19. Lack of effect of inositol treatment in chronic schizophrenia
20. Double-blind controlled trial of inositol treatment of depression
21. Inositol may worsen attention deficit disorder with hyperactivity
22. Inositol treatment of autism
23. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression
24. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: Opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used
25. The Flinders sensitive line rats: A genetic animal model of depression
26. Behavioral despair in rats, a new model sensitive to antidepressant treatments
27. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competative NMDA receptor antagonist
28. 3 receptors in the activity of antidepressants in the mouse forced swimming test
29. 2C antagonists and 8-OH-DPAT in the mouse forced swim test
30. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test
31. Dode-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity
32. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: Implication of noradrenergic and serotonergic mechanisms
33. Pharmacological and functional characterization of D2 D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines
34. Selective dopaminergic mechanism of dopamine and SKF38393 stimulation on inositol phosphate formation in the brain
35. The validity of animal models of depression